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SUMMARY
Over the past decade, wingless-activated (WNT) medulloblastoma has been identified as a candidate for
therapy de-escalation based on excellent survival; however, a paucity of relapses has precluded additional
analyses of markers of relapse. To address this gap in knowledge, an international cohort of 93 molecularly
confirmed WNT MB was assembled, where 5-year progression-free survival is 0.84 (95%, 0.763–0.925) with
15 relapsed individuals identified. Maintenance chemotherapy is identified as a strong predictor of relapse,
with individuals receiving high doses of cyclophosphamide or ifosphamide having only one very late molec-
ularly confirmed relapse (p = 0.032). The anatomical location of recurrence is metastatic in 12 of 15 relapses,
with 8 of 12 metastatic relapses in the lateral ventricles. Maintenance chemotherapy, specifically cumulative
cyclophosphamide doses, is a significant predictor of relapse across WNTMB. Future efforts to de-escalate
therapy need to carefully consider not only the radiation dose but also the chemotherapy regimen and the
propensity for metastatic relapses.
INTRODUCTION
The 2016 World Health Organization (WHO) classification has
stratified medulloblastoma into four molecular groups (wing-
less-activated [WNT], sonic hedgehog-activated [SHH], group
3, and group 4) based on clear biological and clinical differences,
and the current challenge is to define an optimal therapy regimen
for each.1,2 Currently, all children with medulloblastoma are
treated uniformly with surgery followed by craniospinal irradia-
tion and combination chemotherapy, and although these treat-
ments improve outcome, they also result inmajor life-long cogni-
tive, neurological, and neuroendocrine side effects. Across most
prospective and retrospective studies, WNT medullablastoma
(MB) has been recognized as having excellent outcomes with
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current therapy, particularly in patients below the age of 16.3
Hence, WNT MB is the subject of trials of de-escalation of ther-
apy,2,4 with three studies open worldwide for de-escalation of
radiation therapy and one study investigating the role of chemo-
therapy-only regimens (15 Gy, NCT:NCT01878617; 18 Gy,
NCT:NCT02724579 and NCT:NCT02066220; chemotherapy
only, NCT: NCT02212574). Unfortunately, the study investigating
post-surgical chemotherapy only, with maintenance chemo-
therapy according to the ACNS0331 protocol, was stopped pre-
maturely because of an unacceptable number of early failures,
suggesting that a deeper understanding of relapsed WNT MB
is urgently required.5
Although most studies have shown that WNT MB has an
excellent outcome, the relationship between treatment regimen
and outcome is still an area of investigation. Adult WNT MB
was first shown to portend to a poorer outcome, and it has
been suggested that patients with WNT MB over the age of 16
should not be included in trials of de-escalation of therapy.6,7
A review of treatment failures in the European Society for Pediat-
ric Oncology (SIOPe)-PNET4 study revealed a surprisingly high
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number of WNT MB relapses (8 of 58, 14%) using nuclear b-cat-
enin as a marker of WNT activation.8,9 This dedicated study of
relapsed individuals in the SIOPe-PNET4 study reveals that 5
of 8WNT relapses involved individuals under the age of 16. How-
ever, the reliance on nuclear b-catenin to diagnoseWNTMB and
lack of genome-wide methylation-based subgrouping cast
doubt on whether these were simply misdiagnosed.10 It has
been postulated that WNT MB has improved survival because
of an impaired blood-brain barrier, suggesting that chemo-
therapy is an important mainstay of therapy; however, there is
a paucity of literature suggesting that survival may be different
based on treatment.11 Although it is well recognized that WNT
failures do occur, these instances have been poorly character-
ized, and specifically the pattern of relapse and markers of prog-
nosis are unclear. To start addressing these questions, we
assembled a cohort of 93 molecularly confirmed individuals
with WNT MB having received heterogeneous treatment, exam-
ined whether particular treatment regimens might predict prog-
nosis, and observed that use of high-dose cyclophosphamide-
based adjuvant chemotherapy is a strong predictor of outcome.
RESULTS
Demographics and Survival of the Entire Cohort
Ninety-three cases of WNT MB were collected with accompa-
nying clinical information between 1990 and 2017 (Table S1).
The diagnosis of WNT MB was established using genome-
wide methylation profiling, with WNT MB assigned applying
the Heidelberg Brain Tumor Classifier in 84 cases (https://
www.molecularneuropathology.org/mnp). A calibrated score of
0.9 or above is regarded as WNT MB and considered the gold
standard for diagnosis of WNT MB.12 In addition, t-distributed
stochastic neighbor embedding (t-SNE) analysis of the top differ-
entially methylated probes was performed with a cohort of 401
MBs, and all 84 cases cluster tightly with the WNT group. In 63
cases, nanoString limited gene expression profiling of 22 signa-
ture genes was also performed, showing a very strong WNT
signature, with confidence scores exceeding 0.99 in all cases.
In 8 cases, methylation profiling was unavailable, and at least
two methods were employed. In two of these cases, WNT MB
was ascribed using nanoString limited gene expression profiling,
monosomy 6, and b-catenin nuclear immunopositivity, as deter-
mined by an expert pediatric neuropathologist (C.E.H.). In 6
cases, WNT MB was diagnosed by direct sequencing of exon
3 of CTNNB1 and fluorescence in situ hybridization (FISH) for
monosomy 6. Full details of subgrouping methods are provided
in Table S1.
Across the entire cohort, 15 relapsed individuals were identi-
fied, with a 5-year progression-free survival of 0.84 (95% confi-
dence interval [CI], 0.763–0.925) and 5-year overall survival
across the cohort of 0.929 (95% CI, 0.871–0.992) (Figures 1A
and 1B). Considering that this rate of relapse was higher than
in the literature, we performed t-SNE analysis of WNT MB and
confirmed that the 15 relapsed cases clustered tightly with all
WNT MBs as a single entity (Figure 1C). This confirms that
relapsed WNTMB does not form a separate entity and suggests
that other factors are leading to relapse. One late relapse was
identified 15.8 years after diagnosis, and methylation profiling
of primary and relapse confirmed that it was still a WNT MB
and not a radiation-induced glioblastoma. Only one relapsed
case did not have methylation profiling available but was
ascribed a WNT MB using three methods: b-catenin nuclear im-
munopositivity, monosomy 6, and nanoString. Gene expression
arrays were available for 53 cases, including 7 relapses; how-
ever, only 18 differentially expressed genes could be identified
between those with progression and those without, which were
not associated with any single pathway. t-SNE analysis and un-
supervised hierarchical clustering of the top 200 differentially ex-
pressed genes did not showWNTMB relapses segregating as a
distinct group (Figure S1).
Genomic Profiling of a Very Late Relapse
Tissue from diagnosis and relapse was available from a subject
with a relapse in the lateral ventricles 15.8 years post-diagnosis,
treated under the closed protocol CCG9961B. Genome-wide
methylation profiling of this case using the Molecular Neuropa-
thology 2.0 classifier revealed that the primary tumor and the
recurrence still classified as a WNT with a calibrated score
of 0.99, with an identical copy number plot across primary
and relapse (Figure 1D). Pathological review of the relapse
sample was consistent with an MB with b-catenin nuclear
immunopositivity.
Factors Predictive of Relapse
To determine whether any clinical risk factors of relapse could be
identified, we then proceeded to compare relapsed and non-
relapsed WNT MBs. Known risk factors, such as metastatic dis-
ease and extent of resection, showed no difference in survival
(Table 1; Figure S2). Copy number profiles were available in 86
of 93 samples and did not differ between relapsed and non-
relapsed individuals. Monosomy 6 was observed in 92 of 93
samples (98.92%), and 17p loss (a surrogate for TP53mutational
status) was observed in 9 of 86 samples (10.4%), with no differ-
ences in survival discerned (Table 1; Figure S2).13 Specifically,
14 of 15 relapsed individuals harbored monosomy 6 (p = 0.63,
Fisher’s exact test), and 3 of 15 relapsed individuals had 17p
loss (p = 0.61, Fisher’s exact test). Male gender was a significant
predictor of relapse (p = 0.033). Full clinical details of all 15
relapsed WNT MBs are presented in Table 2. When separating
centers by geographical location and/or affiliation with the SIOPe
or Children’s Oncology Group (COG), 6 were COG centers, 6
were SIOPe centers, 1 was in Asia, and 2 were in Eastern Europe
(Table S1). Eight of 14 relapsed individuals received chemo-
therapy according to CCG9961 regimen A, with one late relapse
at 15.8 years treated with CCG9961 regimen B (Table 2).
Of the 15 relapsed individuals, 10 were confirmed to have
died, 4 were alive with disease, and 1 was a confirmed long-
term survivor. The single individual where salvage was possible
was initially treated with a gross total resection and 23.4 Gy of
craniospinal irradiation with a posterior fossa boost to 55.8 Gy,
followed by 8 cycles of cisplatin, CCNU, and vincristine. A
relapse was observed along the ependymal surface of the frontal
horn of the lateral ventricle 18 months post-completion of ther-
apy and treated successfully with oral etoposide induction, fol-
lowed by a single cycle of busulfan and thiotepa with autologous
stem cell transplant and 30 Gy of focal radiation to the frontal




lobes. This individual is currently 16 years post-relapse with no
evidence of disease.
Survival Stratified by Treatment Protocol
Detailed chemotherapy protocols were available in 90 of 93 sub-
jects, and detailed radiotherapy dosage with fields available in
87 of 93 subjects. Twenty-three individuals received craniospinal
radiotherapy only, and although a trend of improved survival in
those receiving maintenance chemotherapy was observed, it
was not significant (hazard ratio [HR], 0.518; 95% CI, 0.1738–
1.545; p = 0.17). Comparison between reduced-dose (23.4 Gy)
and standard-dose (36 Gy or more) craniospinal irradiation did
not result in different survival (Figure S1). Because 9 of 15
relapsed individuals received maintenance chemotherapy, we
sought to determine if there were discrepancies in their treat-
ment regimen. Strikingly, when we divided the cohort based on
cyclophosphamide dosing, those with no or intermediate doses
of cyclophosphamide and/or CCNU-based maintenance (CCNU
± cyclophosphamide% 6 g/m2) and primarily high doses of nitro-
gen mustard-based chemotherapy (cyclophosphamide R 12 g/
m2 or an equivalent dose of ifosphamide), we observed a single
very late failure in those receiving high-dose cyclophosphamide
or ifosphamide therapy (Figure 2). Five-year progression-free




Figure 1. Predictors of Relapse in WNT MB
(A and B) Progression-free (A) and overall (B) survival of WNT MB. Light blue shading represents 95% CIs.
(C) t-SNE visualization of 401 primaryMB samples profiled by genome-widemethylation profiling. WNT cases are divided into those with no relapse, relapse, and
no clinical information.
(D) Copy number plot of a late relapse after 16 years, confirmingmonosomy 6 (WNT subgroup) at diagnosis and relapse. One late death was not confirmed to be a
relapse and was attributed to chronic respiratory failure secondary to long-standing neurological dysfunction and possible tracheostomy failure.




0.574–0.911), and 5-year overall survival was 0.878 (95% CI,
0.757–1), with 7 of 8 relapses occurring within 4 years of radio-
therapy. A multivariable Cox regression analysis confirmed that
this survival difference across maintenance chemotherapy regi-
mens was independent of age at diagnosis, male gender, meta-
static status, and radiation dose (Table S2). Restricting the anal-
ysis to children receiving modern chemotherapy protocols
showed this same pattern, with children on cisplatin and
CCNU-based protocols having significantly inferior survival
than those treated with high-dose cyclophosphamide or ifosfa-
mide (Table S3). Male gender remained a significant predictor
of relapse in the multivariable analysis. An individual aged 2.7
years was treated using a radiation-sparing approach using
CCG99703 comprising 3 induction cycles and 3 high-dose
chemotherapy cycles with autologous stem cell support and is
alive and progression-free 5 years post-completion of therapy.
Taken together, this suggests that high-dose cyclophospha-
mide/ifosfamide-based chemotherapy regimens result in a
significantly improved outcome.
Anatomical Location of Relapse in WNT MB
Finally, we queried the clinical data for any trends suggestive of a
pattern of relapse. The location of relapse was available for all 15
patients; 12 relapsed in the metastatic compartment, 3 relapsed
in the surgical cavity, and one outside of the neuroaxis. Interest-
ingly, of the 11 metastatic relapses, 8 were in the lateral ventri-
cles, with 6 of the 8 restricted to the frontal horn (Table 2). The
remaining 4 were diffuse metastatic relapses, with one being
extraneural.
DISCUSSION
Despite WNT MB considered as having an excellent prognosis,
we observed a relatively high relapse rate of 15% in our cohort.
Although the relapse rate we observed is likely an overestimate
based on the retrospective design of the cohort, the finding
that individuals receiving higher doses of cyclophosphamide
therapy do not relapse suggests that the chemotherapy regimen
administered will be crucial as we reduce radiation doses.
It has been shown previously that WNT-MB has a different
vasculature suggestive of a unique microenvironment, leading
to improved responses to chemotherapy, specifically vincris-
tine.11 Most cohorts have suggested excellent outcomes for
WNT patients with few relapses; however, analysis of relapses
in the PNET4 study suggested that individuals with WNT MB
relapse in almost 15% of cases.8 In PNET3, the 5-year event-
free survival of individuals with WNT MB was 88.9% (3 of 27 re-
lapses), where the cumulative dose of cyclophosphamide was 3
g/m2 in those treated with chemotherapy, and the dose of cra-
niospinal irradiation was 36 Gy.14-16 In contrast, St. Jude’s Me-
dulloblastoma 096 [SJMB96] showed 100% survival with high-
dose cyclophosphamide therapy for individuals with WNT MB,
but this was only a cohort of 10 subjects.17 Our observation of
a confirmed very late relapse ofWNTMBhas not been described
previously and warrants long-term follow-up, particularly with
those enrolled in recently completed trials with available molec-
ular subgrouping. A limitation of these studies could be the reli-
ance on nuclear b-catenin rather than robust subgrouping using
DNA methylation or multiple methods, but these results are
indeed consistent with our findings. Unfortunately, previous trial
cohorts of average-risk medulloblastoma specifically CCG9961
which randomized CCNU to cyclophosphamide, have not been
subgrouped as tissue was not prospectively collected. As
such, a definitive validation of the results of our study are not
possible.18
Indeed, the eventual publication of recently closed trial co-
horts may help validate our finding that high-alkylator therapy
results in improved survival in WNT MB compared with CCNU-
based treatments as prescribed in PNET4 and ACNS0331. Eval-
uating the geographic location of treatment in our cohort, WNT
MB relapses were treated globally, with themajority of cases be-
ing treated at COG or SIOPe centers. In addition, half of the indi-
viduals receiving cyclophosphamide in this cohort were outside
Table 1. Comparison of Demographics and Treatment of WNT
MB, Stratified by Relapse
No Relapse Relapse p Value
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Balanced chromosome 6 10 1
Monosomy 6 66 14
Chromosome 17p 0.19
17p balanced 64 12
17p loss 6 3
GTR, gross total resection; STR, subtotal resection with residual
>1.5 cm2. Cyclophosphamide/ifosfamide includes ICE regimens.
CCNU-based includes treatment according to ACNS0331. Chromo-
somes 6 and 17 are arm-level losses. The p values are from a Fisher’s
exact test, except age at diagnosis was determined using a Mann-Whit-
ney U test. Bold p-values represent values below 0.05.
aR23.4-Gy craniospinal irradiation (CSI) includes 3 patients with 25-Gy
CSI and 2 patients with 30.6-Gy CSI.




of SIOPe or COG centers, suggesting that location of therapy is
not an unobserved variable accounting for our findings.19
In our study, clinical risk factors, such as extent of resection
and metastatic disease, were not significant predictors of
relapse inWNTMB, which is consistent with several previous re-
ports16,19,20. A recent retrospective study across 78WNTMBs
treated at the Burdenko Neurosurgical Institute was also consis-
tent with these clinical risk factors not being significant predic-
tors of outcome.12 Interestingly, this study also had heteroge-
neous maintenance regimens, including treatment according to
St. Jude’s Medulloblastoma 003 [SJMB03] and German Society
of Pediatric Oncology and Hematology (HIT) protocols, but did
not reveal a similar propensity for CCNU-based regimens having
worse outcomes. However, one potential difference is that the
majority of individuals in this series treated with CCG9961
regimen A maintenance chemotherapy (cisplatin, CCNU,
vincristine) also received 36 Gy of craniospinal irradiation, and
high-risk individuals received intrathecal methotrexate. There-
fore, it is plausible that the intensification of therapy in the major-
ity of subjects in this study accounts for the excellent survival
observed. In our cohort, individuals treated with CCG9961A- or
ACNS0331-based regimens received reduced-dose craniospi-
nal irradiation of 23.4 Gy. It has been suggested that individuals
with WNT MB over the age of 16 are a higher-risk group; how-
ever, in our cohort, age was not a significant risk factor for
relapse, and 13 of 14 relapses were in individuals 16 years of
age or younger.3,9 Moreover, previous observations that adults
with WNT MB do poorly may pertain to the frequent omission of
chemotherapy in this group rather than any biological risk
factors.6
Our findings have profound implications for the design of
de-escalation studies for WNT MB and suggest that serious
consideration should be given to the chemotherapy regimen.
Recently, a study of surgery and chemotherapy only was sus-
pended to accrual after an unacceptable number of relapses
(NCT: NCT02212574).5 In this study, only chemotherapy was
administered, according to ACNS0331,with 6 g/m2 of cyclophos-
phamide and 450 mg/m2 of CCNU. Several studies of radiation
reduction are ongoing through the Children’s Oncology Group
(ACNS1422 and NCT: NCT02724579), SIOPe (PNET5 and
NCT: NCT02066220), and St. Jude’s (SJMB12 and NCT:
NCT01878617). Completion of these studies with appropriate
follow-up will take at least another decade; however, our findings
should serve as awarning that future efforts to de-escalate the ra-
diation dose inWNTMBwill likely require careful consideration of
the chemotherapyprotocol andat least 12g/m2of cyclophospha-
mide. An intriguing possibility is use of radiation-sparing proto-
cols, such as Headstart or CCG99703; however, WNT MB is
rare in infancy, resulting in a paucity of preliminary data with this
approach. Although cyclophosphamide-based protocols have a
less favorable toxicity profile (specifically, ovarian failure in fe-
males, alopecia, and more profound myelosuppression), our re-
sults suggest that, when designing studies of de-escalation of
therapy, the chemotherapy regimen needs to be accounted for.
Table 2. Subject Characteristics and Survival of 15 Relapsed WNT MBs
ID
Age (years)/
Gender Stage OS (Years) PFS (Years) Relapse Pattern CSI Dose (Gy) Initial Chemotherapy Status
1 15.0/M M0 2 1.4 diffuse mets 23.4 8 in 1a DOD
2 18.5/M M0 4.9b 4.8 frontal horn lateral ventricles 40.0 none died
3 10.0/F M0 4.0 2.7 tumor bed 36.0 carbo/CTX/VPc DOD
4 9.0/M M1 13.2 6.3 diffuse mets 36.0 carbo/CTX/VPc DOD
5 7.7/M M0 1.0 1.0 extraneural 35.2 none AWD
6 56.3/M M2 8.6 4 tumor bed 34.2 none AWD
7 10.5/F M0 7.8 2.8 frontal horn lateral ventricles 23.4 9961Ad DOD
8 9.9/M M0 3.5 1 frontal horn lateral ventricles 23.4 ACNS0331e DOD
9 11/M M0 2.5 2.5 frontal horn lateral ventricles 23.4 9961Ad AWD
10 6.4/M M0 17 1.4 frontal horn lateral ventricles 23.4 9961Ad alive
11 16.0/F M0 6.6 2.4 frontal horn lateral ventricles 23.4 9961Ad DOD
12 9.5/F M0 5.0 4.1 diffuse mets 36.0 cisplatin, vincristine ANED
13 11.2/F M0 4.5 1.6 tumor bed 36.0 9961Ad AWD
14 13.7/M M0 1.6 2.8 lateral ventricles and spinal 23.4 9961Ad DOD
15 12/F M0 15.8 16.4 lateral ventricles 23.4 9961Bf DOD
AWD, alive with disease; ANED, alive with no evidence of disease; DOD, dead of disease; CSI, craniospinal irradiation; CTX, cyclophosphamide; VP,
VP16.
aChemotherapy scheme with vincristine, hydroxyurea, procarbazine, CCNU, cisplatin, cytosine arabinoside (Ara-C), methylprednisolone, and either
cyclophosphamide in 1 day.
bDied of massive hemorrhage.
cNeo-adjuvant chemotherapy (PNET III).
d9961A chemotherapy consists of 8 cycles of cisplatin, CCNU, and vincristine.
eACNS0331 chemotherapy consists of 9 cycles of AABAABAAB, with A cycles having cisplatin, CCNU, and vincristine and B cycles having cyclophos-
phamide with vincristine.
f9961B chemotherapy consists of 8 cycles of cisplatin, cyclophosphamide, and vincristine.




Our study reveals that WNT MB has a unique pattern of
relapse, with a significant proportion of relapses in the lateral
ventricles, with the remainder of failures in the surgical tumor
bed or the leptomeninges. We reported previously that the
pattern of relapse in MB is highly subgroup specific, with SHH
recurring in the surgical cavity in 50%–60% of instances and
groups 3 and 4 recurring almost exclusively in the leptomeninges
in previously irradiated individuals.21 In this previous study, the
pattern of relapse in WNT MB could not be evaluated because
of a paucity of cases; our observations add significantly to our
understanding of the pattern of relapse and suggest that the
ependymal lining is a unique microenvironment conducive to
WNT MB. Generation of additional WNT MB models will be
required to fully discern the biological implications of this finding,
but potential options to de-escalate therapy may include direct
intraommaya delivery of chemotherapy to the lateral ventricles.
A limitation of our findings is its retrospective design and lack
of tissue from all relapsed samples. Indeed, it has become more
apparent that a significant subset of MB relapses, particularly
late relapses, are, in fact, radiation-induced glioblastoma, but
our one relapse is still a WNT MB 15 years after diagnosis.
Consideration for biopsy at relapse with genome-wide methyl-
ation profiling should be undertaken in future studies to exclude
this possibility, although radiation-induced glioblastoma typi-
cally arises at least 5 years post-diagnosis.22,23 Furthermore,
our study is limited by a lack of granularity regarding the quality
of radiotherapy and adherence to protocol, which may account
for unobserved variables portending relapse. Our retrospective
design may also result in overestimation of relapses, suggesting
that the difference between treatment regimens in trial cohorts
may, in fact, be considerably less pronounced. However, the
retrospective heterogeneous treatment across our cohort al-
lowed us to identify that the chemotherapy protocol is potentially
an important predictor of outcome. In the future, a pooled anal-
ysis of trial cohorts will be necessary to address this issue. Our
study highlights the importance of incorporating specific treat-
ment protocols when evaluating retrospective biologically strat-
ified data, which can provide robust hypothesis generation to be
tested and validated in prospective studies.
Overall, our findings significantly advance our understanding
of the clinical behavior of WNT MB and provide several key in-
sights to help inform future treatment protocols aimed at de-
escalating therapy. Future studies ofWNTMBmedulloblastoma,
particularly those aimed at therapy de-escalation, need to give
careful consideration to the maintenance chemotherapy proto-
col and the unique pattern of relapse observed in this subgroup.
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Vijay
Ramaswamy (vijay.ramaswamy@sickkids.ca), Assistant Professor, Departments of Medical Biophysics and Paediatrics, University
of Toronto; Division of Haematology/Oncology, Hospital for Sick Children, Toronto, ON, Canada.
Materials Availability
This study did not generate new, unique reagents.
Data and Code Availability
The DNA methylation datasets unique to this study are available at Mendeley Data, https://doi.org/10.17632/cw37zdmgm3.2
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human Subjects
We assembled a cohort of 93 cases of molecularly confirmed WNT medulloblastoma identified through the Medulloblastoma
Advanced Genomics International Consortium, the Hospital for Sick Children, the Royal Children’s Hospital Melbourne and the Uni-
versity Hospital Motol in Prague. Treatment details including radiation dose and field, chemotherapy protocol, extent of surgical
resection, gender and survival were available and discerned via retrospective chart review (Table 1; Complete Demographics avail-
able in Table S1). Updated clinical data with treatment annotations were obtained for WNT-MB cases previously published in Cavalli
et al.24 WNT subgroup was ascribed using genome wide methylation arrays in 84 patients, specifically a calibrated score above 0.9
using the Molecular Neuropathology 2.0 algorithm (https://www.molecularneuropathology.org/mnp) and t-SNE analysis with a
REAGENT or RESOURCE SOURCE IDENTIFIER
Biological Samples
93 primary medulloblastoma samples 24; This study N/A
Critical Commercial Assays
Infinium HumanMethylation450 BeadChip Kit Illumina, San Diego, USA N/A
Infinium MethylationEPIC BeadChip Kit Illumina, San Diego, USA N/A
Deposited Data
Methylation array data (53 previously published
samples)
24 GEO: GSE85218 (Table S1)
Expression array (53 previously published samples) 24 GEO: GSE85217 (Table S1)
Methylation array data (30 unpublished samples) This study Mendeley, https://doi.org/10.17632/
cw37zdmgm3.2 (Table S1)
Software and Algorithms




Conumee (v.1.8.0) 26 https://bioconductor.org/packages/
release/bioc/html/conumee.html
Molecular Neuropathology 2.0 27 https://www.molecularneuropathology.
org/mnp
Rtsne (v 0.11.17) 28 https://cran.r-project.org/web/packages/
Rtsne/index.html
Multiple Experiment Viewer (MeV) 29 http://mev.tm4.org
R2: Genomics Analysis and Visualization Platform R2 Support Team, Amsterdam
Medical Center
https://hgserver1.amc.nl:443/




published cohort of medulloblastoma (GEO: GSE85218). Fifty-three samples were profiled using Affimetrix Human Gene 1.1 ST
Arrays (GEO: GSE85217). Array number and .idat file identifiers are included in Table S1. An additional 2 samples were included
based on the presence of clear nuclear beta-catenin accumulation, monosomy 6 by SNP array and a strong signature of WNT-
MB by nanoString limited gene expression profiling, and an additional 6 samples were included based on concurrent mutation in
exon 3 of beta-catenin and monosomy 6. All samples and clinical annotations were collected in accordance to research institutional
review boards at participating institutions and at the Hospital for Sick Children.
METHOD DETAILS
DNA Methylation Profiling
Samples were analyzed on the Illumina Infinium HumanMethylation450 or Illumina MethylationEPIC arrays at the PM-OICR Trans-
lational Genomics Laboratory or the Center for Applied Genomics (Toronto, ON) according to manufacturer’s instructions as previ-
ously described.24,30 All analysis was conducted in the R Statistical Environment (v3.4.1). Raw data files (.idat) generated by the
Illumina iScan array scanner from both frozen and FFPE derived tissue were loaded and pre-processed using the minfi package
(v1.22.1).25 Illumina pre-processing was selected to mimic the normalization performed in Illumina Genome Studio. Methylation
beta values were calculated as described in Illumina’s protocols. Subsequently, the following filtering criteria were applied: Removal
of probes targeting the X and Y chromosomes (n = 11,551), removal of probes containing a single nucleotide polymorphism
(dbSNP132 Common) within five base pairs of and including the targeted CpG-site (n = 24,536), and probes not mapping uniquely
to the human reference genome (hg19) allowing for one mismatch (n = 9,993). In total, 438,370 probes were kept for analysis. Me-
dulloblastoma subgroup was ascribed using the Heidelberg brain tumor classifier (https://www.molecularneuropathology.org/mnp).
In order to consider distinct molecular signatures, we performed unsupervised clustering of DNAmethylation data generated from
previously published cases clearly identified as one of the four subgroups by the Heidelberg Brain Tumor Classifier.24,27 In addition,
we repeated unsupervised clustering only for samples which were classified as WNT MB. For unsupervised clustering, we selected
the most variable probes with a median absolute deviation > 0.25. Distance between samples was calculated using Pearson corre-
lation coefficient as the distance measure and the same distance matrix was used to perform the t-distributed stochastic neighbor
embedding (tSNE) analysis using the Rtsne package version 0.11.17. The following nondefault parameters were used: theta = 0,
is_distance = T, pca = F, max_iter = 10000.28 Copy number profiles were generated using the ‘conumee’ package (v1.8.0) as pre-
viously described.26
Gene Expression Analysis
Fifty-three samples were previously published using Affymetrix Human Gene 1.1 ST Arrays (GEO: GSE85217), and analysis
conducted in the R2: Genomics Analysis and Visualization Platform (https://hgserver1.amc.nl:443/) and within the Multi Experiment
Viewer. Samples were normalized using RMA in R2, and t-SNE analysis performed within R2 comparing recurrent versus non-recur-
rent WNT-MB. Differential gene expression was performed comparing relapsed and non-relapsed WNT-MB using ANOVA and an
FDR of 0.01, and pathway analysis performed using KEGG and GO terms. Unsupervised hierarchical clustering was performed in
the Multi Experiment Viewer (MeV_4_8) using the top 200 differentially expressed genes ranked by median absolute deviation.29
QUANTIFICATION AND STATISTICAL ANALYSIS
Complete subject data can be found in Table S1, with details of statistical tests found in the figure legends and table footers. Pro-
gression-free survival and overall survival were analyzed by the Kaplan-Meier method and p values reported using the log-rank
test. Associations between covariates and risk groups were tested by the Fishers exact test. Multivariable cox proportional hazard
regression was performed using Firth’s penalized maximum likelihood bias reduction method to estimate hazard ratios including
95% confidence intervals. The proportional-hazards assumption was tested using the cox.zph function in the survival package
and graphical inspection of Schoenfeld residual plots, and was not statistically significant for any of the co-variates. All statistical
analyses were performed in the R statistical environment (v3.6.0), using R packages survival (v2.41-3), coxphf (v1.13) and ggplot2
(v2.2.1).
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Supplemental Figure 1 (Related to Figure 1): Unsupervised clustering of differentially 
expressed genes stratified by progression.  A) t-SNE analysis of top differentially 
expressed genes comparing relapsed and non-relapsed cases, perplexity=10.  B) 
Unsupervised hierarchical clustering of the top 200 differentially expressed genes. 
 
Supplemental Figure 2 (Related to Figure 2):  Univariable analysis of clinical and 
cytogenetic risk factors across WNT medulloblastoma.  Progression free survival stratified 
by A) Metastatic status, B) Extent of surgical resection, C) Monosomy 6, D) 17p status, 
E) gender, F) craniospinal irradiation dose.  P-values determined using the log-rank test. 
 
Supplemental Figure 3 (Related to Figure 2): Impact of maintenance chemotherapy on 
survival in WNT medulloblastoma.  A) Progression-Free Survival and B) Overall Survival 
of WNT medulloblastoma stratified by patients receiving radiation only, non-
cyclophosphamide or high dose cyclophosphamide/ifosphamide based maintenance 
chemotherapy regimens.  P-values determined using the log-rank test. 
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Table S2 (related to Table 2): Multivariable analysis of progression-free survival across 
cases of WNT medulloblastoma 
 
Legend: Low Cyclo – cyclophosphamide < 6g/m2.  CSI – craniospinal irradiation 
 
Variable HR 95% CI p-value 
Age 1.02 0.97-1.08 0.32 
Male Gender 4.75 1.55-15.53 0.0079 
Maintenance Chemotherapy    
CCNU/Low Cyclo vs 
Radiation Alone 
0.98 0.30-3.34 0.97 
Cyclo based vs 
Radiation Alone 
0.13 0.013-0.68 0.014 
Cyclo based vs 
CCNU/Low Cyclo 
0.16 0.020-0.72 0.015 
Standard vs reduced dose 
CSI 
0.98 0.89-1.08 0.76 
Metastatic Dissemination 1.45 0.25-14.31 0.69 
Monosomy 6 2.53 0.54-25.55 0.27 
 
Table S3 (Related to Table 2): Multivariable analysis of progression-free survival across 
cases of WNT medulloblastoma treated only on modern protocols (n=63)  
 





Variable HR 95% CI p-value 
Age 1 0.83-1.19 0.98 
Male Gender 3.3 0.83-13.1 0.09 
Maintenance Chemotherapy    
Cyclo based vs 
CCNU/Low Cyclo 
0.14 0.016-0.65 0.009 
Standard vs reduced dose 
CSI 
0.93 0.79-1.05 0.26 
Metastatic Dissemination 0.78 0.04-194 0.26 
    
